PL2324853T3 - Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2 - Google Patents

Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2

Info

Publication number
PL2324853T3
PL2324853T3 PL09175876T PL09175876T PL2324853T3 PL 2324853 T3 PL2324853 T3 PL 2324853T3 PL 09175876 T PL09175876 T PL 09175876T PL 09175876 T PL09175876 T PL 09175876T PL 2324853 T3 PL2324853 T3 PL 2324853T3
Authority
PL
Poland
Prior art keywords
lixisenatide
metformin
add
treatment
diabetes type
Prior art date
Application number
PL09175876T
Other languages
English (en)
Inventor
Louise Silvestre
Caroline Sert-Langeron
Tianyue Zhou
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41728467&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2324853(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PL2324853T3 publication Critical patent/PL2324853T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL09175876T 2009-11-13 2009-11-13 Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2 PL2324853T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09175876.3A EP2324853B1 (en) 2009-11-13 2009-11-13 Lixisenatide as add-on to metformin in the treatment of diabetes type 2

Publications (1)

Publication Number Publication Date
PL2324853T3 true PL2324853T3 (pl) 2016-01-29

Family

ID=41728467

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09175876T PL2324853T3 (pl) 2009-11-13 2009-11-13 Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2

Country Status (9)

Country Link
EP (1) EP2324853B1 (pl)
CY (1) CY1117603T1 (pl)
DK (1) DK2324853T3 (pl)
ES (1) ES2553593T3 (pl)
HR (1) HRP20151230T1 (pl)
HU (1) HUE026489T2 (pl)
PL (1) PL2324853T3 (pl)
PT (1) PT2324853E (pl)
SI (1) SI2324853T1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
RU2572703C2 (ru) * 2011-02-02 2016-01-20 Санофи-Авентис Дойчланд Гмбх Предотвращение гипогликемии у пациентов с сахарным диабетом 2 типа
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20130040878A1 (en) * 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients
US8735349B2 (en) 2011-05-13 2014-05-27 Sanofi-Aventis Deutschland Gmbh Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
ES2556466T3 (es) 2011-05-13 2016-01-18 Sanofi-Aventis Deutschland Gmbh Lixisenatida y metformina para el tratamiento de la diabetes tipo 2
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI706779B (zh) * 2015-01-16 2020-10-11 德商賽諾菲阿凡提斯德意志有限公司 小兒第２型糖尿病病患之治療
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JP2023528565A (ja) 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
EP4141008A4 (en) 2020-04-01 2024-04-17 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. PHARMACEUTICALLY ACCEPTABLE ACID SALT OF GLP-1 RECEPTOR AGONIST FREE BASE, AND PREPARATION METHOD THEREFOR

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels

Also Published As

Publication number Publication date
HUE026489T2 (en) 2016-06-28
HRP20151230T1 (hr) 2015-12-18
SI2324853T1 (sl) 2015-12-31
PT2324853E (pt) 2015-11-30
EP2324853B1 (en) 2015-08-26
ES2553593T3 (es) 2015-12-10
EP2324853A1 (en) 2011-05-25
DK2324853T3 (en) 2015-11-30
CY1117603T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
SI2324853T1 (sl) Liksisenatid kot dodatek metforminu pri zdravljenju sladkorne bolezni tipa 2
HRP20121029T1 (hr) Liksisenatid kao pomoä†na terapija uz inzulin glargin i metformin kod lijeäśenja dijabetesa tip 2
ZA200902374B (en) Compositions useful for the treatment of diabetes
ZA201001832B (en) Improvements relating to fabric treatment compositions
ZA201001428B (en) Improvements relating to fabric treatment compositions
PL2707015T3 (pl) Liksysenatyd jako terapia uzupełniająca do insuliny bazalnej w cukrzycy typu 2
PL2707017T3 (pl) Liksisenatyd i metformina do leczenia cukrzycy typu 2
IL249941A0 (en) Spiro-oxaindole substances and medical preparations containing them
PL2143429T3 (pl) Zastosowanie cylastatyny do zmniejszania nefrotoksyczności różnych związków
IL223289A0 (en) Treatment of type 2 diabetes
ZA201103930B (en) Improvements relating to fabric treatment compositions
IL208463A (en) 2-Trotocyclic-Pirol compounds combined, pharmaceutical preparations containing them and their use in the prevention or treatment of diabetes or obesity
PT2842555T (pt) Derivados-alfa de ácidos gordos cis-monoinsaturados para uso como medicamentos no tratamento de diabetes
ZA201001831B (en) Improvements relating to fabric treatment compositions
ZA201103931B (en) Improvements relating to fabric treatment compositions
ZA201001830B (en) Improvements relating to fabric treatment compositions
GB0724739D0 (en) Improvements relating to fabric treatment compositions
IL200192A0 (en) Composition useful for the treatment of type 2 diabetes
PL2315651T3 (pl) Zastosowanie mediatorów przy produkcji płyt pilśniowych
GB0821594D0 (en) Improvements in or relating to the treatment of tissue damage
GB0904709D0 (en) Improvements in or relating to the transformation of clothing
EP2384338A4 (en) GLP-1 ANALOGS AND THEIR APPLICATIONS
GB0723159D0 (en) Crockery to which cultery can be attached
GB0809469D0 (en) Improvements relating to body jewelry
GB0910889D0 (en) Improvements in or relating to treatment tables